When tumor cells are too far from blood supply, the different signals associated with hypoxia will be emitted. This will trigger the complex remodeling process called angiogenesis. It is associated with an increase in the tumor malignancy and propensity to invade other tissues. Cancer cells will secrete different factors to harness the vascular system in order to irrigate the tumor. (1,2) CD105 (or Endoglin) is upregulated in hypoxic conditions and we can assess its presence in tumoral tissue when angiogenesis is triggered. CD105 presence in tumor tissue is associated in many different cancer with a poor prognosis.(3) TRC105 a therapeutic antibody targeting CD105 is actually going through the different clinical phase as a new weapon to inhibit angiogenesis in cancer treatment. (4,5) As part of our MédiMabs-CCAB series, we offer you an anti-CD105 (MM-0300) and hope it will help you to assess its presence in your different experiments.